Original Articles

Prostate-specific membrane antigen (PSMA) as diagnostic biomarker in prostate cancer: a cross-sectional study

Lucky Frannata, Indrawarman Soeroharjo , Raden Danarto, Didik Setyo Heriyanto

Lucky Frannata
Department of Surgery, Division of Urology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sardjito General Hospital, Yogyakarta

Indrawarman Soeroharjo
Department of Surgery, Division of Urology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sardjito General Hospital, Yogyakarta. Email: indrawarman@ugm.ac.id

Raden Danarto
Department of Surgery, Division of Urology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sardjito General Hospital, Yogyakarta

Didik Setyo Heriyanto
Department of Pathology Anatomy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sardjito General Hospital, Yogyakarta
Online First: May 26, 2021 | Cite this Article
Frannata, L., Soeroharjo, I., Danarto, R., Heriyanto, D. 2021. Prostate-specific membrane antigen (PSMA) as diagnostic biomarker in prostate cancer: a cross-sectional study. Indonesia Journal of Biomedical Science 15(1): 68-70. DOI:10.15562/ijbs.v15i1.309


Introduction: Prostate cancer is the second most common malignancy among men in the world.  Prostate-specific membrane antigen (PSMA), a type II membrane protein, is produced by all prostate cells in any stage of prostate malignancy. This recently recognized attribute may prove useful in future diagnosis and therapy of prostate cancer. The aim of this study was to compare PSMA expression in both prostate cancer and benign prostate disease.

Methods: PSMA antigen expression was examined using polymerase chain reaction (PCR). Total of 20 samples from each prostate cancer and benign prostate group were examined at the Department of Pathology Anatomy, Dr. Sardjito Hospital. The data was analyzed using version 21 of SPSS.

Results: The mean PSMA gene expression in benign groups was 13.49 [95% CI: 11.27 – 15.72] and the mean PSMA gene expression in the malignant group was: 25.14 [95% CI: 20.95-29.33], the p-value was <0.01. Using an independent T-test analysis, we found that the increase in PSMA gene expression in the prostate cancer group was statistically significant.

Conclusion: The expression of the PSMA gene was correlated with prostate cancer. Increased PSMA gene expression in prostate tissue could be used as a biomarker to diagnose prostate cancer.

References

Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pacific J Cancer Prev. 2014;15(22):9575-9578.

Castillejos-molina RA, Gabilondo-navarro FB. Castillejos-Molina. Prostate cancer. Salud Publica Mex. 2016;58(2):279-284.

Jakobsen NA, Hamdy FC, Bryant RJ. Novel biomarkers for the detection of prostate cancer. J Clin Urol. 2016;9:3-10.

Wright GL, Haley C, Beckett M Lou, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol Semin Orig Investig. 1995;1(1):18-28.

Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6:13-8.

Cullen J, Kuo HC, Shan J, Lu R, Aboushwareb T, Van Den Eeden SK. The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer. Urology. 2020;1-9.

Ristau BT, O’Keefe DS, Bacich DJ. The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research. Urol Oncol Semin Orig Investig. 2014;32(3):272-279.

Demirkol MO, Acar Ö, Uçar B, Ramazanoʇlu SR, Saʇlican Y, Esen TDLDAL. Prostate-specific membrane antigen-based imaging in prostate cancer: Impact on clinical decision making process. Prostate. 2015;75(7):748-757.

Bouchelouche K, Choyke PL, Capala J. Prostate Specific Membrane Antigen-A Target for Imaging and Therapy with Radionuclides. Discov Med. 2010;9(44):55-61.

Hupe MC, Philippi C, Offermann A. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. Front Oncol. 2018;8:623.

Dorff TB, Fanti Stefano, Farolfi A, Reiter RE, Sadun TY, Sartor O. The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. American Society of Clinical Oncology.2021.

Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, Giorgi UD, Tumedei NM, Raulli G. Scientific Reports. 2018;8:4254

Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson, WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Load M, Mucci LA. Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention. 2013;22(12):2354-63

Jemaa AB, Bouraoui Y, Sallami S, Banasr A, Nouira Y, Oueslati R. PSMA/PSA Ratio Evaluated by Immunohistochemistry May Improve Diagnosis of Prostate Cancer. Journal of Immunoassay and Immunochemistry 2014;35(1)

Gorges TM, Riethdorf S, Ahsen OV, Nastaly P, Rock K, Boede M, Peine S, Kuske A, Schmid E, Kneip C, Konig C, Rudolph M, Pantel K. Heterogeneous PSMA expression on circulating tumor cells – a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget. 2016;7:34930-34941


Article Views      : 0
PDF Downloads : 0